---
title: "IRIDEX CORP 1Q 2026: Revenue $11.8M, EPS $(0.03) — 10-Q Summary"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286962517.md"
description: "IRIDEX CORP reported Q1 2026 revenue of $11.8M, a slight decrease from $11.9M a year ago, with a narrowed net loss of $0.52M compared to $1.69M previously. Diluted EPS improved to $(0.03) from $(0.10). Glaucoma sales rose 14.5%, while retina sales fell 12.3%. Management anticipates current cash will sustain operations for at least 12 months, focusing on cost savings and R&D discipline."
datetime: "2026-05-19T20:21:02.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286962517.md)
  - [en](https://longbridge.com/en/news/286962517.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286962517.md)
---

# IRIDEX CORP 1Q 2026: Revenue $11.8M, EPS $(0.03) — 10-Q Summary

IRIDEX CORP reported first-quarter 2026 results showing essentially flat revenue and a narrower loss versus the year-ago quarter: revenue was $11.8M and diluted EPS was $(0.03), with net loss of $0.52M compared with a $1.69M loss a year earlier.

**Financial Highlights**

-   Revenue was $11.799M for Q1 2026, compared with $11.896M in the year-ago quarter; YoY change (0.8%).
-   Net income (loss) was a loss of $0.524M for Q1 2026, compared with a loss of $1.686M in the year-ago quarter (loss narrowed).
-   Diluted EPS was $(0.03) for Q1 2026, compared with $(0.10) in the year-ago quarter.

**Business Highlights**

-   Total revenues were essentially flat with glaucoma sales up 14.5% offset by a 12.3% decline in retina sales.
-   U.S. and Germany sales are managed directly; international distribution is largely through Topcon and other distributors, with noted FX exposure on Euro-denominated sales.
-   Continued adoption of MicroPulse® and Endpoint Management™ across glaucoma and retina product lines is driving recurring consumable probe revenue.
-   Gross margin was pressured by higher manufacturing and tariff-related costs as the company shifts production toward lower-cost contract manufacturers.
-   Management expects current cash to fund operations for at least 12 months and is focused on cost savings, R&D discipline, and preserving service and consumable revenue streams.

Original SEC Filing: IRIDEX CORP \[ IRIX \] - 10-Q - May. 19, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### Related Stocks

- [IRIX.US](https://longbridge.com/en/quote/IRIX.US.md)
- [XHE.US](https://longbridge.com/en/quote/XHE.US.md)
- [IHI.US](https://longbridge.com/en/quote/IHI.US.md)
- [7732.JP](https://longbridge.com/en/quote/7732.JP.md)

## Related News & Research

- [Edwards Lifesciences CVP, Strategy/Corp Development Sold Shares Worth Over $1.4M](https://longbridge.com/en/news/286822028.md)
- [Lifeward Delays Quarterly Report Amid Deal Accounting](https://longbridge.com/en/news/286586728.md)
- [Coherent Corp. Rocked by Major Insider Stock Move From Company Director](https://longbridge.com/en/news/286343834.md)
- [Stryker Buys Amplitude Vascular Systems For Upto $835 Mln To Expand Vascular Treatment Business](https://longbridge.com/en/news/286889480.md)
- [Boston Scientific Targets Growing Aortic Stenosis Market With $1.5 Billion Deal](https://longbridge.com/en/news/286808399.md)